To test whether KML001’s effects on Akt and PTEN are limited to glioma cell lines, we employed prostate (Du145 and PC-3) and breast cancer (MDA-MB-231 and BT-549) cell lines with different PTEN expression statuses. This evidence concerns the gene AKT1 and central nervous system cancer.